Company intelligence / Profile preview

Sangart

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Sangart developed the MP4 platform to deliver oxygen or carbon monoxide to ischemic tissues. Its lead program, MP4OX for traumatic hemorrhage, failed a Phase IIb trial on its primary endpoint but showed some secondary efficacy signals with no major safety concerns. The sickle cell program, MP4CO, completed a successful Phase Ib trial. The company ceased operations after failing to secure further funding following these results.

Therapeutic areas: Hematology
Modalities: Recombinant proteinProtein (pegylated human hemoglobin)Small molecule (carbon monoxide delivery)
Industry: Biotech

Beyond the preview

Go deeper on Sangart.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sangart.

Explore the full profile